542 related articles for article (PubMed ID: 22684647)
1. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions.
Tylicki L; Lizakowski S; Rutkowski B
J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647
[TBL] [Abstract][Full Text] [Related]
2. Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives.
Tylicki L; Larczynski W; Rutkowski B
Kidney Blood Press Res; 2005; 28(4):230-42. PubMed ID: 16127280
[TBL] [Abstract][Full Text] [Related]
3. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
Bomback AS; Toto R
Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
[TBL] [Abstract][Full Text] [Related]
4. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
5. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
6. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trails.
Rutkowski B; Tylicki L
J Ren Nutr; 2015 Mar; 25(2):194-200. PubMed ID: 25576239
[TBL] [Abstract][Full Text] [Related]
7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
8. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
9. [Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].
Horký K
Vnitr Lek; 2010 Feb; 56(2):120-6. PubMed ID: 20329582
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
[TBL] [Abstract][Full Text] [Related]
12. [Lights and shadows on single and dual RAAS blockade].
Cavalli A; Del Vecchio L; Locatelli F
G Ital Nefrol; 2010; 27(5):477-89. PubMed ID: 20922679
[TBL] [Abstract][Full Text] [Related]
13. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
15. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
Toto R; Palmer BF
Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
[TBL] [Abstract][Full Text] [Related]
17. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.
Berl T
J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):1-8. PubMed ID: 19286752
[TBL] [Abstract][Full Text] [Related]
18. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
19. The Remission Clinic approach to halt the progression of kidney disease.
;
J Nephrol; 2011; 24(3):274-81. PubMed ID: 21534237
[TBL] [Abstract][Full Text] [Related]
20. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?
Ryan MJ; Tuttle KR
Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
